Title: Advanced Lung Cancer Inflammation Index  A Key Predictor of Hepatic Steatosis and
Fibrosis Severity
Version: 2 Date: 07 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
Methods Age limitations should be stressed Comorbidities should be defined and anyone of
them ending up in patient exclusion from the study should be reported Moreover all chronic
liver diseases apart from MASLD should be an exclusion criterion Alcohol consumption should
be defined and MASLD should be differentiated from MetSLD Number of patients in the study
belong to the results as well as those excluded for various reasons Any condition leading in liver
congestion like clinically significant heart failure should be taken into consideration Evaluation
in the three discrimination margins for F2,F3 and F4 could be more informative Results could
include changes according to LSM stratification in F2, F3 and F4 patients
Title: Advanced Lung Cancer Inflammation Index  A Key Predictor of Hepatic Steatosis and
Fibrosis Severity
Version: 2 Date: 07 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
Methods Age limitations should be stressed Comorbidities should be defined and anyone of
them ending up in patient exclusion from the study should be reported Moreover all chronic
liver diseases apart from MASLD should be an exclusion criterion Alcohol consumption should
be defined and MASLD should be differentiated from MetSLD Number of patients in the study
belong to the results as well as those excluded for various reasons Any condition leading in liver
congestion like clinically significant heart failure should be taken into consideration Evaluation
in the three discrimination margins for F2,F3 and F4 could be more informative Results could
include changes according to LSM stratification in F2, F3 and F4 patients
Please review this paper.
user
Title: Advanced Lung Cancer Inflammation Index  A Key Predictor of Hepatic Steatosis and
Fibrosis Severity
Version: 2 Date: 07 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
Methods Age limitations should be stressed Comorbidities should be defined and anyone of
them ending up in patient exclusion from the study should be reported Moreover all chronic
liver diseases apart from MASLD should be an exclusion criterion Alcohol consumption should
be defined and MASLD should be differentiated from MetSLD Number of patients in the study
belong to the results as well as those excluded for various reasons Any condition leading in liver
congestion like clinically significant heart failure should be taken into consideration Evaluation
in the three discrimination margins for F2,F3 and F4 could be more informative Results could
include changes according to LSM stratification in F2, F3 and F4 patients
assistant